If you look at the link already provided several times, see the date at the top.
It's dated October 18th.
The report is of course great. BUT, the key is in what Garza wrote in BM Reports. The key is what the good Doc is going say about the LEAPs platform, anti-inflammatory qualities and application for other treatments. How it strengthens the body's immune system to fight, and unlike fighting against itself as with other auto immune diseases, it specifically targets the cells that have gone awry, avoiding cytokyne storm. (Did he write that? I hope so)
All my opinion.
the anti-inflamatory properties are the key here. They apply for both diseases.
Look at this description for RA's symptoms-- They Sound EXACTLY like Flu symptoms:
The disease usually begins gradually with:
* Loss of appetite
* Morning stiffness (lasting more than 1 hour)
* Widespread muscle aches
Dont get me wrong I love this stock and think cel-2000 has great potential for arthritis, but I know cel-sci is more concerned right know with phase 3 of multikine and h1n1 treatment. Imo the good news out of this would be a license agreement, but imo they need to get phase 1 started. The science cel-sci has it what will shed the light on them, and have a lot of people watching them. all I am saying is cel-2000 is more long term. but we still have great short term things coming. just dont want people to have high hopes, for this weekend and end up selling if nothing happens and noone buys out cel-sci
people dont expect alot out of this weekend, for one cel-2000 for arthritist is only through pre-clinical trails, still has not started phase one. I do love this stock but the short term is phase 3 of multikine and h1n1 treatment. cel-2000 is great but I never invest because of preclinical data
calhouncorso, I think the scientist see years ahead, not today! That means partnerships like TEVA! I disagree with your summary on the presentation on Sunday! Remember you have big pharma at this presentation and one right contact takes CVM out in a buyout!